Skip to main content
. Author manuscript; available in PMC: 2007 Oct 27.
Published in final edited form as: J Control Release. 2006 Aug 30;115(3):289–297. doi: 10.1016/j.jconrel.2006.08.015

Figure 5.

Figure 5

Changes in anti-factor Xa activity after nasal administration of enoxaparin formulated in saline or in the presence of different concentrations of (A) PEI-25KDa, (B) PEI-750KDa, or (C) PEI-1000KDa. Data represent mean ± SEM, n=3–5.